Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MGEN Miragen Therapeutics (MGEN) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsTrends About Miragen Therapeutics Stock (NASDAQ:MGEN) 30 days 90 days 365 days Advanced Chart Ad WealthPressCould TSLA reach $500 a share? Free ebook says it’s possible.Even though shares of Tesla are only up 3% this year, one man believes Tesla’s next bull run is just around the corner. In his professional opinion, the share price could reach $500 or more… Now, we understand that may seem far-fetched, but as you’ll see in his new ebook, it’s not as crazy as it may sound. In fact, he argues a Trump presidency could make it happen much faster than you might think. which is why we’re emailing you now… For the time being, he’s giving away his Tesla ebook for free. Inside explains how shares could reach $500 in the near future.To claim your copy, follow this link Get Miragen Therapeutics alerts:Sign Up Key Stats Today's Range$21.70▼$22.9950-Day Range$14.34▼$23.0152-Week Range$4.66▼$34.05Volume591,343 shsAverage Volume134,027 shsMarket Capitalization$89.26 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewMiragen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high-unmet medical need. Its four lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous and ocular fibrosis, which is in Phase II clinical trial; MRG-229, which is in preclinical trial for the treatment of idiopathic pulmonary fibrosis; and MRG- 110, an inhibitor of miR-92, a microRNA expressed in endothelial cells, which has completed two Phase I clinical trial for the treatment of heart failure, wound healing, and other ischemic disease in the United States and Japan. Miragen Therapeutics, Inc. was founded in 2006 and is based in Boulder, Colorado.Read More… Could TSLA reach $500 a share? Free ebook says it’s possible. (Ad)Even though shares of Tesla are only up 3% this year, one man believes Tesla’s next bull run is just around the corner. In his professional opinion, the share price could reach $500 or more… Now, we understand that may seem far-fetched, but as you’ll see in his new ebook, it’s not as crazy as it may sound. In fact, he argues a Trump presidency could make it happen much faster than you might think. which is why we’re emailing you now… For the time being, he’s giving away his Tesla ebook for free. Inside explains how shares could reach $500 in the near future.To claim your copy, follow this link Receive MGEN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Miragen Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address MGEN Stock News HeadlinesAmgen and MediLink to collaborate on SCLC combination therapyOctober 10, 2024 | msn.comWhy Biotech Giant Amgen Stands A Chance Of Taking On Novo, Lilly In ObesityAugust 7, 2024 | msn.comMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicted the 2020 crash a month before it happened...November 5, 2024 | Opportunistic Trader (Ad)AMGN Earnings: Amgen Stock Down on Mixed Q2 ResultsAugust 7, 2024 | msn.comAmgen Undercuts Its Buy Point On Mixed Second-Quarter ReportAugust 6, 2024 | msn.comMiragen Therapeutics is about to announce earnings — here's what Wall Street expectsMay 7, 2024 | markets.businessinsider.comViridian Therapeutics Inc (VRDN)January 30, 2024 | investing.comSee More Headlines MGEN Stock Analysis - Frequently Asked Questions How were Miragen Therapeutics' earnings last quarter? Miragen Therapeutics, Inc. (NASDAQ:MGEN) released its earnings results on Tuesday, November, 10th. The medical research company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.03. Miragen Therapeutics had a negative net margin of 1,393.50% and a negative trailing twelve-month return on equity of 141.66%. What other stocks do shareholders of Miragen Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Miragen Therapeutics investors own include Sorrento Therapeutics (SRNE), OPKO Health (OPK), Nokia Oyj (NOK), VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Onconova Therapeutics (ONTX) and Pfizer (PFE). Company Calendar Last Earnings11/10/2020Today11/05/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical Laboratories Sub-IndustryN/A Current SymbolNASDAQ:MGEN CUSIPN/A CIK1590750 Webwww.signalgenetics.com Phone720-643-5200FaxN/AEmployees45Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($20.09) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,870,000.00 Net Margins-1,393.50% Pretax MarginN/A Return on Equity-141.66% Return on Assets-88.74% Debt Debt-to-Equity Ratio0.20 Current Ratio4.23 Quick Ratio4.23 Sales & Book Value Annual Sales$4.46 million Price / Sales20.01 Cash FlowN/A Price / Cash FlowN/A Book Value$6.78 per share Price / Book3.37Miscellaneous Outstanding Shares3,908,000Free FloatN/AMarket Cap$89.26 million OptionableNot Optionable Beta1.66 Unlock the Potential in Options TradingOptions trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.Get This Free Report This page (NASDAQ:MGEN) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredMissed Out On Nvidia?Artificial Intelligence is a tool with the potential to create massive distributions of wealth… In fact, it...Unstoppable Prosperity | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Miragen Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Miragen Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.